STORM Therapeutics Expands Scientific Advisory Board with the Appointment of Professor Tsutomu Suzuki
STORM Therapeutics today announces the appointment of Professor Tsutomu Suzuki to its Scientific Advisory Board (SAB)
Cambridge, UK, 8 March 2021: STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, today announces the appointment of Professor Tsutomu Suzuki to its Scientific Advisory Board (SAB).
Dr. Tsutomu Suzuki is a professor at the department of chemistry and biotechnology in University of Tokyo, Japan. His research centres on RNA biochemistry, especially on the biogenesis and function of RNA modifications, and molecular mechanisms of protein synthesis. His group has developed their platform technologies for isolating individual RNAs, and for highly sensitive analysis of RNA modifications by mass spectrometry; discovered several novel modifications and dozens of RNA-modifying enzymes; and also reported the first instance of human disease caused by disrupted RNA modification, and is now studying the molecular pathogenesis of this disease.
Dr. Keith Blundy, CEO of STORM Therapeutics, said: “As one of the world leading experts in RNA biochemistry, we are pleased to welcome Professor Tsutomu Suzuki to STORM’s Scientific Advisory Board. Tsutomu’s expertise will be invaluable to STORM as we accelerate the development of STC-15, STORM’s first-in-class drug candidate targeting METTL3, towards first in human clinical studies.”
STORM Therapeutics is the leading company currently tackling disease through modulating RNA modifying enzymes. It recently announced the contribution of a comprehensive review on the role of RNA-Modifying Enzymes and their inhibitors, in 2020 Medicinal Chemistry Reviews, Volume 55.
STORM Therapeutics Ltd
T: +44 (0)1223 804174
Optimum Strategic Communications
Mary Clark, Eva Haas, Shabnam Bashir
Tel: +44 (0)203 950 9144
NOTES TO EDITORS
STORM Therapeutics, founded in 2015, is a University of Cambridge spin-out translating the ground-breaking work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into the discovery of first-in-class drugs in oncology and other diseases. Storm is the leading company tackling disease through modulating RNA modifying enzymes and is developing a unique platform and pipeline to address these enzyme classes, including RNA methyltransferases.
STORM is backed by blue chip investors Cambridge Innovation Capital, M Ventures, Pfizer Ventures, Taiho Ventures LLC, Seroba Life Sciences and IP Group, who share the team’s ambitions to build a world-leading company in the field.